A tissue microarray (TMA) of lung adenocarcinomas obtained from the the University of Pittsburgh Lung Specialized Program of Research Excellence (SPORE) was stained for ATM at the Biomarker Division of AstraZeneca in Cambridge, UK. Here, ATM is linked to lung adenocarcinoma.